Literature DB >> 11079714

Effects of NaCN and ionomycin on neuronal viability and on the abundance of microtubule-associated proteins MAP1, MAP2, and tau in isolated chick cortical neurons.

B Hutter-Paier1, E Grygar, M Loibner, G Skofitsch, M Windisch.   

Abstract

The effects of two toxins, sodium cyanide (NaCN) and ionomycin (IM), on neuronal viability and on the expression of the microtubule-associated proteins MAP1, MAP2, and tau were studied in isolated chick cortical neurons. Cytotoxic hypoxia due to NaCN treatment was performed to mimic acute neuronal damage, whereas long-term IM treatment was used as a model for chronic neuronal impairment. After 5 days in vitro, a cytotoxic lesion was induced either by addition of NaCN (0.01-10 mM) or IM (0.01-10 microM). The NaCN solution was aspirated after 30 min and cells were allowed to regenerate for 6 h, 24 h, 48 h, or 72 h; whereas the permanent IM lesions were left undisturbed during the same periods of time. Neuronal viability was assessed by MTT assay. The abundance of MAP1, MAP2, and tau was evaluated by immunoblotting and, for MAP2, by immunohistochemistry also. Results showed that NaCN and IM lesions dose-dependently decreased viability. Irreversible cell damage occurred after impairment with 10 mM NaCN and 1 microm or 10 microm IM, while neurons lesioned with lower concentrations regenerated partially or adapted to the toxic environment. However, the same level of viability as of untreated cells was never reached. Furthermore abundance of MAPs was changed after both lesions. But while after extended recovery from NaCN lesion protein expression was normalizing (MAP2) or at least still detectable (MAP1A, tau), the consequences of a permanent IM lesion were more severe, since neurons were not able to maintain or even restore their MAP expression. Immunohistochemical experiments for MAP2 revealed that, compared with controls, NaCN and, to a much higher extent, IM treatment resulted in a loss of immunoreactivity in neurites due to progressing cell death.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079714     DOI: 10.1007/s004410000258

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  6 in total

1.  N-PEP-12--a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions.

Authors:  M Windisch; B Hutter-Paier; E Grygar; E Doppler; H Moessler
Journal:  J Neural Transm (Vienna)       Date:  2005-03-07       Impact factor: 3.575

2.  Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window.

Authors:  E Schauer; R Wronski; J Patockova; H Moessler; E Doppler; B Hutter-Paier; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

3.  MAP-2 expression in the human adenohypophysis and in pituitary adenomas. An immunohistochemical study.

Authors:  Fabio Rotondo; Kenichi Oniya; Kalman Kovacs; C David Bell; Bernd W Scheithauer
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  Axotomy-Induced Changes of the Protein Profile in the Crayfish Ventral Cord Ganglia.

Authors:  Svetlana Demyanenko; Valentina Dzreyan; Anatoly Uzdensky
Journal:  J Mol Neurosci       Date:  2019-05-07       Impact factor: 3.444

5.  Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury.

Authors:  Ying Wang; Yansong Li; Shawn L Dalle Lucca; Milomir Simovic; George C Tsokos; Jurandir J Dalle Lucca
Journal:  J Neuroinflammation       Date:  2010-04-09       Impact factor: 8.322

6.  In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury-Lessons Learned.

Authors:  Anssi Lipponen; Teemu Natunen; Mika Hujo; Robert Ciszek; Elina Hämäläinen; Jussi Tohka; Mikko Hiltunen; Jussi Paananen; David Poulsen; Emilia Kansanen; Xavier Ekolle Ndode-Ekane; Anna-Liisa Levonen; Asla Pitkänen
Journal:  Int J Mol Sci       Date:  2019-10-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.